Alzheimerís Disease (AD) is a devastating neurological disease that affects more than 37 million people worldwide. The presence and accumulation of beta-amyloid in the brain and the self-assembly of hyper-phosphorylated tau protein tangles are thought to contribute to the development and pathogenesis of AD.
Parkinsonís Disease (PD) is a degenerative disease of the central nervous system resulting in the loss of dopamine-producing cells in the brain. Leucine-rich repeat kinase 2 or LRRK2 (also now classified as PARK8) became of great interest in 2004 when it was identified as the second autosomal dominant PD gene involving a toxic gain of function. Biosensis was the first company to offer high quality sheep and rabbit antibodies against LRRK2.